<table>
<thead>
<tr>
<th>January</th>
<th>February</th>
<th>March</th>
<th>April</th>
<th>May</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticipating immuno-oncology modality/platform development trends for 2022</td>
<td>Dissecting investor and market access trends and drivers for I-O R&amp;D insights</td>
<td>Optimizing clinical development strategy for the rapidly evolving I-O field</td>
<td>Novel target and pathways: driving new approaches to tackling the TME and resistance to I-O therapeutics</td>
<td>Combination therapy development: strategic directions towards improving current I-O response rates</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>June</th>
<th>July</th>
<th>September</th>
<th>October</th>
<th>November</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety: what progress in understanding and addressing immune-related adverse events?</td>
<td>How to move towards precision I-O? Innovation in biomarker R&amp;D</td>
<td>Nonclinical tools update: are they improving in their capabilities of predicting clinical responses?</td>
<td>Leveraging the cutting-edge TME toolkit</td>
<td>Combination therapy development: emerging I-O therapeutic modalities and predictive technologies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>December</th>
<th>February 2023</th>
<th>March 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immuno-Oncology Insights’ annual exploration of enabling tools and therapeutic technology platforms likely to make a splash in 2023</td>
<td>Nonclinical tools update: emerging technologies</td>
<td>Optimizing clinical development strategy</td>
</tr>
</tbody>
</table>

Each spotlight will comprise:
- Peer-reviewed Reviews and Expert Insight articles written by leading experts in the field
- Webinars, featuring industry speakers and sponsors discussing key topics specific to the Spotlight
- Podcast, written and video interviews with key opinion leaders
- On demand roundtable discussions

Immu-Onco Insights’ spotlights provide you with fantastic opportunities to:
- Educate your target market about your company’s expertise, capabilities and experience
- Share your latest data with organizations looking for partners and service providers in your field
- Profile your executives and scientists as thought-leaders and KOLs
- Generate qualified leads from across the global sector
- Increase awareness of your company’s role in immuno-oncology R&D
<table>
<thead>
<tr>
<th>JANUARY</th>
<th>FEBRUARY</th>
<th>MARCH</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anticipating immuno-oncology modality/platform development trends for 2022</strong></td>
<td><strong>Dissecting investor and market access trends and drivers for I-O R&amp;D insights</strong></td>
<td><strong>Optimizing clinical development strategy for the rapidly evolving I-O field</strong></td>
</tr>
<tr>
<td>‣ Tumor-mediated immune suppression: beyond PD-1</td>
<td>‣ What are investors’ and analysts’ reflections on current vibrant market sentiment and associated VC/IPO activity, and their expectations for future financing trends in the I-O space? And what is their message for industry decision-makers?</td>
<td>‣ Expanding the reach of immuno-oncology</td>
</tr>
<tr>
<td>‣ What next for TIGIT and LAG-3? (And will further checkpoint inhibitor opportunities arise?)</td>
<td>‣ How will the market evaluate larger (but crowded) indications vs niche indications for I-O agents moving forward?</td>
<td>‣ Examining novel clinical trial endpoints in I-O studies – what’s being considered across the field? Developers and regulator perspectives</td>
</tr>
<tr>
<td>‣ Exploring various mechanisms and their future relevance to the I-O field (eg. TGF-β)</td>
<td>‣ What are the implications for patients, clinicians, regulators, and the field as a whole of recent I-O product withdrawals following conditional approvals?</td>
<td>‣ Examining clinical development strategies and data for I-O agents in earlier lines of treatment/stages of disease – what lessons can the field take moving forward?</td>
</tr>
<tr>
<td>‣ Examining the near-mid-term prospects and development trends for next-generation cellular immunotherapy</td>
<td>‣ Mounting competition in the PD-1/PD-L1 arena: what will be the repercussions for:</td>
<td>‣ What does data obtained so far tell us about future I-O applications in the neoadjuvant and adjuvant settings?</td>
</tr>
<tr>
<td>‣ How is the new wave of autologous CAR T cell immunotherapies set to build on the clinical success of first and second generation approaches?</td>
<td>‣ Checkpoint inhibitor pricing and reimbursement? (Will we see a price war? What does that mean for the I-O industry, if so?)</td>
<td>‣ How to approach the challenge of addressing metastatic disease with I-O?</td>
</tr>
<tr>
<td>‣ Allogeneic cellular immunotherapy – how are safety and efficacy obstacles being addressed in early clinical studies (eg. through gene editing)?</td>
<td>‣ When will we see the first PD-1 biosimilar? What will be its expected impact?</td>
<td>‣ What next for patients who acquire resistance to I-O drugs?</td>
</tr>
<tr>
<td>‣ What progress in engaging and harnessing innate immune system mechanisms against solid tumors? (eg. NK cells, γδ T cells, TLR or STING agonists)</td>
<td>‣ Combination therapy development strategy across the I-O sector?</td>
<td>‣ What is needed at the strategic and practical levels to enable AI and machine learning to fully permeate the I-O space?</td>
</tr>
<tr>
<td>‣ Next-gen CARs (eg. TRUCKS and multi-targeted CARs, CAR macrophages)</td>
<td>‣ What novel/innovative pricing and reimbursement models are best suited to next-generation I-O therapeutics, particularly as they move into earlier lines of therapy? (Eg. pay by performance models)</td>
<td>‣ Allowing the integration of disparate data sets for efficient clinical development</td>
</tr>
<tr>
<td>‣ Are cancer vaccines back to stay? Assessing progress in alleviating long-standing delivery and target selection challenges</td>
<td>‣ How can the community as a whole work to increase patient access to I-O therapeutics on a global basis?</td>
<td>‣ How to anticipate and alleviate the ongoing/future impact of COVID-19 pandemic-related disruption on immuno-oncology therapeutic clinical development?</td>
</tr>
<tr>
<td>‣ Personalized neoantigen-based cancer vaccines</td>
<td></td>
<td>‣ Where is clinical trial design innovation required by the immuno-oncology space?</td>
</tr>
<tr>
<td>‣ Oncolytic virotherapy: How are various platforms and payloads stacking up?</td>
<td></td>
<td>‣ Addressing the growing issue of underpowered early-phase trials</td>
</tr>
<tr>
<td>‣ What might the future combination therapy picture look like?</td>
<td></td>
<td>‣ Harnessing the potential of adaptive trial designs for the I-O field</td>
</tr>
<tr>
<td>‣ How to leverage in patients with systemic metastatic disease?</td>
<td></td>
<td>‣ How to approach the challenge of predicting and planning for future standards of care when you are in early development?</td>
</tr>
<tr>
<td>‣ A pivotal year for bi-/tri-specific T cell engagers: are novel targets resulting in reduced toxicity and enhanced T cell activation in the clinic/against solid tumors?</td>
<td></td>
<td>‣ Evolving approaches to the intensifying I-O patient recruitment challenge (particularly for biomarker-heavy studies)</td>
</tr>
<tr>
<td>‣ Cytokines: next steps in the development and I-O application of IL-2, IL-15, IL-18, etc.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**APRIL**

**Novel target and pathways: driving new approaches to tackling the TME and resistance to I-O therapeutics**
- What are the key enabling technologies enhancing novel target identification and validation for antibody therapeutics and cellular immunotherapies? Exploring their capabilities and considerations for practical application
- What tools can assist in targeting tumor-associated antigens? (e.g., MHC, peptide recognition)
- Evaluating cellular immunotherapies (CAR T, TCR, NK, etc.) and bi/multispecific antibody therapies in solid tumor indications
- Optimal approaches to improve specificity (e.g., enhancing bispecific antibody avidity)
- Which novel targets and pathways are showing promise in improving response rates, efficacy?
  - Understanding mechanisms of resistance (e.g., to CAR T cell therapy in melanoma)
  - Targeting multiple antigens
  - What are the next steps towards personalizing immuno-oncology therapy to the individual TME?
- What progress with approaches to break up the tumor stroma, thus enabling penetration of TILs and other therapeutics?

**JULY**

**How to move towards precision I-O? Innovation in biomarker R&D**
- Assessing the current state of play and identifying next steps in terms of discovering and developing reliable markers of response in solid tumors
- What new directions in biomarker discovery can novel and emerging I-O agents open up for the field (e.g., LAG-3, cellular immunotherapies)?
- What do resistance markers tell us about how to harness the innate immune system moving forward?
- Exploring the cutting-edge in imaging tools and their application in I-O (e.g., PET-based tracer studies to monitor immune response; leveraging early imaging predictors to gain an idea of response; delivering non-invasive markers of disease)
- What are the next steps for the field in capitalizing on the potential of single cell sequencing and analysis tools?
  - Mass cytometry for simultaneous multiple marker analysis
    - Harnessing CyTOF (cytometry by time of flight) in combination with spatial imaging
  - Applying AI and machine learning to integrate biomarker data (e.g., with longitudinal patient data) – what is practical both now and in the future?
- Evaluating the potential of circulating plasma exosomes
- What is the latest thinking in terms of the role of the microbiome and its impact on immune response?
- Who will fund and drive the high-risk/high-reward novel biomarker research required by the I-O field moving forward?

**SEPTEMBER**

**Nonclinical tools update: are they improving in their capabilities of predicting clinical responses?**
- Developing and validating appropriate cell models and organoids
- How to harness preclinical predictivity for co-stimulatory molecules?
- Why aren’t preclinical models of antigen-specific T cells predictive of clinical success?
- How and where is the combination of preclinical and clinico-genomic data helping predict patient response?
- What are the keys to further accelerating speed to IND in the I-O space?
- Regulatory perspective: how to approach nonclinical toxicology studies for personalized I-O therapeutics given the lack of good animal models available?
- How to address cost and capability issues (of current DNA synthesis platforms, for example) to ensure continued advancement of synthetic biology in the I-O space?
- How should we reconsider or redesign our R&D approach from discovery onwards if we are targeting second- or third-line treatment with I-O agents from the get-go?

**OCTOBER**

**Leveraging the cutting-edge TME toolkit**
- What is the current extent of our understanding of the ‘how’ and ‘why’ of hot and cold tumors?
- Promising pathways to addressing the issue of T cell exhaustion
- What are the relevant dendritic cells in human tumors?
- How and where is the application of key enabling technologies unlocking the secrets of the TME and tumor resistance to advance the immuno-oncology field?
- Multiomics approaches (genomics, proteomics, transcriptomics)
- Single cell analysis
  - Single cell RNA analysis (e.g., of TILs)
  - Non-invasive spatial imaging
  - What can high parameter cytometry (flow and mass) tell us about cell-to-cell interactions in the TME?
  - Recent progress in understanding and measuring metabolism in situ in the TME (e.g., measuring pH as a sign of immunoregulation)
- How to better utilize these tools to gain further insights into I-O mechanisms of action? (e.g., why do checkpoint inhibitors work?)
- How to address key data integration issues in deriving insights from novel analytical tools, particularly in terms of integration with disparate preclinical and clinical datasets?
<table>
<thead>
<tr>
<th>November</th>
<th>December</th>
<th>February 2023</th>
</tr>
</thead>
</table>
| **Combination therapy development: emerging I-O therapeutic modalities and predictive technologies**  
- How and where are next-gen sequencing and analytical tools being effectively applied to improve predictability of safety and efficacy in the combination setting?  
- Reviewing combination therapy considerations and challenges, and defining next steps, for:  
  - Bi/trispecific antibodies  
    - How to alleviate heightened toxicity risk for T cell redirection agents in combination?  
  - Cellular immunotherapies  
    - Which tools are delivering insights into optimal combinations for CAR T cell and other cellular immunotherapies?  
    - What are optimal pre-conditioning regimens in the solid tumor setting?  
    - Exploring the logic of combining innate and adaptive immune system approaches  
  - Oncolytic virotherapies  
    - What can the latest clinical outcomes from regimens combining anti-PD-1 antibodies with intra-lesional therapies (TLR, STING, oncolytic viruses) tell us about their ability to impact distant disease sites?  
| **Tools of tomorrow**  
- Immuno-Oncology Insights’ annual exploration of enabling tools and therapeutic technology platforms likely to make a splash in 2023  
| **Nonclinical tools update: emerging technologies**  
- Emerging animal models. (How to better humanize immune-compromised mice? Utilizing bespoke CRISPR-derived 'gene of interest' mice)  
- Developing and validating appropriate cell models and organoids  
  - *In vitro versus in vivo* models, 3D cell technologies  
- What can resected tumors tell us about what changes in the TME following I-O dosing?  
| **Optimizing clinical development strategy**  
- Expanding the reach of immuno-oncology  
- Examining novel clinical trial endpoints in I-O studies – what’s being considered across the field? Developers and regulator perspectives  
- Examining clinical development strategies and data for I-O agents in earlier lines of treatment/stages of disease – what lessons can the field take moving forward?  
  - What does data obtained so far tell us about future I-O applications in the neoadjuvant and adjuvant settings?  
  - How to approach the challenge of addressing metastatic disease with I-O?  
  - What next for patients who acquire resistance to I-O drugs?  
- What is needed at the strategic and practical levels to enable AI and machine learning to fully permeate the I-O space?  
- Allowing the integration of disparate data sets for efficient clinical development  
- How to anticipate and alleviate the ongoing/future impact of COVID-19 pandemic-related disruption on immuno-oncology therapeutic clinical development?  
- Where is clinical trial design innovation required by the immuno-oncology space?  
- Addressing the growing issue of underpowered early-phase trials  
- Harnessing the potential of adaptive trial designs for the I-O field  
- How to approach the challenge of predicting and planning for future standards of care when you are in early development?  
- Evolving approaches to the intensifying I-O patient recruitment challenge (particularly for biomarker-heavy studies)  

**Each spotlight will comprise:**  
- Peer-reviewed Reviews and Expert Insight articles written by leading experts in the field  
- Webinars, featuring industry speakers and sponsors discussing key topics specific to the Spotlight  
- Podcast, written and video interviews with key opinion leaders  
- On demand roundtable discussions  

**Immuno-Oncology Insights’ spotlights provide you with fantastic opportunities to:**  
- **Educate your target market** about your company’s expertise, capabilities and experience  
- **Share your latest data** with organisations looking for partners and service providers in your field  
- **Profile your executives and scientists** as thought-leaders and KOLs  
- **Generate qualified leads** from across the global sector  
- **Increase awareness** of your company’s role in cell and gene therapy R&D and manufacture.